Comparative Pharmacology
Head-to-head clinical analysis: POSIMIR versus XYLOCAINE 1 5 W DEXTROSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POSIMIR versus XYLOCAINE 1 5 W DEXTROSE 7 5.
POSIMIR vs XYLOCAINE 1.5% W/ DEXTROSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.
Lidocaine is an amide-type local anesthetic that blocks sodium channels, thereby inhibiting the propagation of action potentials in peripheral nerves, leading to local anesthesia.
Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 mL (66 mg) of the 1.32% solution.
Spinal anesthesia: 1.5-2 mL (22.5-30 mg lidocaine) for lower extremity or perineal procedures; 2-3 mL (30-45 mg) for lower abdominal or urological procedures. Administered via lumbar puncture.
None Documented
None Documented
Terminal elimination half-life is approximately 27 hours (range 16-38 hours), supporting once-daily dosing in clinical use.
Terminal elimination half-life: 1.5–2 hours in adults with normal hepatic function; may be prolonged to 3–5 hours in patients with hepatic impairment or congestive heart failure.
Primarily hepatic metabolism via CYP3A4 and CYP1A2 to inactive metabolites; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of total clearance.
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and conjugates) accounts for >80% of elimination; less than 10% eliminated unchanged in urine. Biliary/fecal excretion of metabolites contributes <10%.
Category C
Category C
Local Anesthetic
Local Anesthetic